Cited by 509Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Open access

Sos, Martin L., Koker, Mirjam, Weir, Barbara A., Heynck, Stefanie, Rabinovsky, Rosalia, Zander, Thomas, Seeger, Jens M., Weiss, Jonathan, Fischer, Florian, Frommolt, Peter, Michel, Kathrin, Peifer, Martin, Mermel, Craig, Girard, Luc, Peyton, Michael, Gazdar, Adi F., Minna, John D., Garraway, Levi A., Kashkar, Hamid, Pao, William, Meyerson, Matthew, Thomas, Roman K.·2009·Cancer Research

DOI 10.1158/0008-5472.can-08-4055PMC PMC2849653

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET. Additional mechanisms contributing to EGFR inhibitor resistance remain elusive. By applying combined analyses of gene expression, copy number, and biochemical analyses of EGFR inhibitor responsiveness, we identified homozygous loss of PTEN to segregate EGFR-dependent and EGFR-independent cells. We show that in EGFR-dependent cells, PTEN loss partially uncouples mutant EGFR from downstream signaling and activates EGFR, thereby contributing to erlotinib resistance. The clinical relevance of our findings is supported by the observation of PTEN loss in 1 out of 24 primary EGFR-mutant non-small cell lung cancer (NSCLC) tumors. These results suggest a novel resistance mechanism in EGFR-mutant NSCLC involving PTEN loss.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-4055

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citation
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Self-citation
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 933
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706
Signaling networks assembled by oncogenic EGFR and c-Met
Guo, A., Villén, J., Kornhauser, J. M., Lee, K. A., Stokes, M. P., Rikova, K., Possemato, A. P., Nardone, J., Innocenti, G., Wetzel, R. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707270105 · Cited by 511
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
She, Q., Solit, D. B., Ye, Q., O'Reilly, K. E., Lobo, J. M., & Rosen, N. X. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 416

Show all 21 references

Sorted by citations

Items 201–300 of 509

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
Rosell, R., Cardona, A. F., Arrieta, O. G., Aguilar, A., Ito, M., Pedraz‐Valdunciel, C., Codony‐Servat, J., & Santarpía, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01519-2 · Cited by 48
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies
Winn, R. A., Sechler, Cizmic, Avasarala, Scoyk, V., Brzezinski, Bikkavilli, & Kelley (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s26058 · Cited by 45
Curcumin mediated down‐regulation of αVβ3 integrin and up‐regulation of pyruvate dehydrogenase kinase 4 (PDK4) in Erlotinib resistant SW480 colon cancer cells
Javadi, S., Rostamizadeh, K., Hejazi, J., Parsa, M., & Fathi, M. (2017) · Phytotherapy Research · doi:10.1002/ptr.5984 · Cited by 45
The Role of PTEN in Tumor Angiogenesis
Rodriguez, S., & Huynh‐Do, U. (2011) · Journal of Oncology · doi:10.1155/2012/141236 · Cited by 44
Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells
Serizawa, M., Takahashi, T., Yamamoto, N., & Koh, Y. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318279e942 · Cited by 44
Challenges in the clinical development of PI3K inhibitors
Massacesi, C., di Tomaso, E., Fretault, N., & Hirawat, S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12060 · Cited by 45
Tyrosine Kinase Inhibitors in Lung Cancer
Thomas, A., Rajan, A., & Giaccone, G. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.001 · Cited by 45
Erlotinib
Petit-Jean, E., Buclin, T., Guidi, M., Quoix, É., Gourieux, B., Decosterd, L. A., Gairard-Dory, A., Ubeaud-Séquier, G., & Widmer, N. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000097 · Cited by 43
Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Hu, J., Zhang, H., Cao, M., Wang, L., Wu, S., & Fang, B. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1173 · Cited by 46
Roles of protein kinase B Akt in lung cancer
Cho, M.-H. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e206 · Cited by 42
Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation
Pazarentzos, E., Giannikopoulos, P., Hrustanovic, G., John, J. S., Olivas, V. R., Gubens, M. A., Balassanian, R., Weissman, J. S., Polkinghorn, W. R., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.173 · Cited by 41
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Vichas, A., Riley, A. K., Nkinsi, N. T., Kamlapurkar, S., Parrish, P. C. R., Lo, A., Duke, F. F., Chen, J., Fung, I., Watson, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24841-y · Cited by 43
Apoptosis Induced by Benzyl Isothiocyanate in Gefitinib-Resistant Lung Cancer Cells is Associated with Akt/MAPK Pathways and Generation of Reactive Oxygen Species
Liu, B., Yan, H., Wu, X., Pan, Z., Zhu, Y. T., Meng, Z., Zhou, Q., & Xu, K. (2012) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-012-9456-9 · Cited by 40
Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
Kim, H. R., Cho, B. C., Shim, H. S., Lim, S. M., Kim, S. I., Chang, J., Kim, D. J., & Kim, J. H. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.011 · Cited by 40
Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Liu, T., Hu, W., Dalton, H. J., Choi, H. J., Huang, J., Kang, Y., Pradeep, S., Miyake, T. M., Song, J. H., Wen, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1305 · Cited by 40
Downregulation of miR-21 increases cisplatin sensitivity of non–small-cell lung cancer
Xu, L., Huang, Y., Chen, D., He, J.-Y., Zhu, W., Zhang, Y., & Liu, X. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.04.003 · Cited by 42
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression
Lin, C., Huang, Y., Cho, C.-F., Lin, Y., Lo, C.-C., Kuo, T.-T., Tseng, G., Cheng, W., Chang, W., Hsiao, T., et al. (2020) · Theranostics · doi:10.7150/thno.49425 · Cited by 38
Lung Adenocarcinoma: Lessons in Translation from Bench to Bedside
Sangodkar, J., Katz, S., Melville, H., & Narla, G. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20226 · Cited by 38
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
Kim, D., Lee, S., Lee, J. S., Lee, M. A., Kang, J. H., Kim, S. Y., Shin, S. W., Kim, H.-K., & Heo, D. S. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.04.005 · Cited by 38
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression
Bidkhori, G., Moeini, A., & Masoudi‐Nejad, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048004 · Cited by 38
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
Henry, R. E., Barry, E., Castriotta, L., Ladd, B., Markovets, A. A., Beran, G. J., Ren, Y., Zhou, F., Adam, A., Zinda, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10859 · Cited by 39
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
Chiba, M., Togashi, Y., Bannno, E., Kobayashi, Y., Nakamura, Y., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3263-z · Cited by 38
PTEN Physically Interacts with and Regulates E2F1-mediated Transcription in Lung Cancer
Malaney, P., Palumbo, E., Semidey-Hurtado, J., Hardee, J., Stanford, K., Kathiriya, J. J., Patel, D., Tian, Z., Allen‐Gipson, D., & Davé, V. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1388970 · Cited by 38
Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma WithEGFR-Activating Mutations
Yuan, S., Yu, S., Chen, H., Hsu, Y., Su, K., Chen, H., Chen, C., Yu, C., Shih, J., Chang, Y., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3979 · Cited by 38
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib
Bessette, D. C., Tilch, E., Seidens, T., Quinn, M. C. J., Wiegmans, A. P., Shi, W., Cocciardi, S., Reed, A. E. M., Saunus, J. M., Simpson, P. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125232 · Cited by 36
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
Paradoxical induction of growth arrest and apoptosis by EGF via the up-regulation of PTEN by activating Redox factor-1/Egr-1 in human lung cancer cells
Ryu, J., Choe, S. S., Ryu, S.-H., Park, E., Lee, B. W., Kim, T. K., Ha, C. H., & Lee, S.-W. (2016) · Oncotarget · doi:10.18632/oncotarget.13809 · Cited by 40
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells
Wang, M., & Chang, A. Y.-C. (2018) · OncoTarget · doi:10.18632/oncotarget.24814 · Cited by 32
Preclinical studies reveal that LSD 1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations
Macheleidt, I. F., Dalvi, P. S., Lim, S., Meemboor, S., Meder, L., Käsgen, O., Müller, M., Kleemann, K., Wang, L., Nürnberg, P., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12382 · Cited by 37
Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model
Li, H., Wang, S., Takayama, K., Harada, T., Okamoto, I., Iwama, E., Fujii, A., Ota, K., Hidaka, N., Kawano, Y., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.017 · Cited by 37
EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN
Li, Z., Qiu, R., Qiu, X., & Tian, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22860 · Cited by 36
Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384
Zhu, Y., & Shah, K. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28585 · Cited by 36
Expression of PTEN and mTOR in pancreatic neuroendocrine tumors
Han, X., Ji, Y., Zhao, J., Xu, X., & Lou, W. (2013) · Tumor Biology · doi:10.1007/s13277-013-0849-1 · Cited by 34
Cancer Immunotherapy: The Dawn of Antibody Cocktails
Marrocco, I., Romaniello, D., & Yarden, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_2 · Cited by 36
Fluorescent kinase inhibitors as probes in cancer
Usama, S. M., Zhao, B., & Burgess, K. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00017a · Cited by 35
Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
Sitthideatphaiboon, P., Teerapakpinyo, C., Korphaisarn, K., Leelayuwatanakul, N., Pornpatrananrak, N., Poungvarin, N., Chantranuwat, P., Shuangshoti, S., Aporntewan, C., Chintanapakdee, W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06239-y · Cited by 37
Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems
Doumat, G., Daher, D., Zerdan, M. B., Nasra, N., Bahmad, H. F., Recine, M. A., & Poppiti, R. (2023) · Current Oncology · doi:10.3390/curroncol30010055 · Cited by 36
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors
Song, J. M., Anandharaj, A., Upadhyaya, P., Kirtane, A. R., Kim, J. H., Hong, K. H., Panyam, J., & Kassie, F. (2016) · Oncotarget · doi:10.18632/oncotarget.10759 · Cited by 34
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
Pan, Y., Jiao, L., Lin, C., Lu, C., Li, L., Chen, H., Wang, Y., & He, Y. (2018) · Biologics · doi:10.2147/btt.s166867 · Cited by 35
YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction
Dai, C.-H., Shu, Y., Chen, P., Wu, J., Zhu, L.-H., Yuan, R., Long, W., Zhu, Y., & Li, J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.015 · Cited by 33
PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541
Hägerstrand, D., Lindh, M. B., Peña, C., Garcı́a-Echeverrı́a, C., Nistér, M., Hofmann, F., & Östman, A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq029 · Cited by 34
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Hayes, T. K., Aquilanti, E., Persky, N. S., Yang, X., Kim, E. E., Brenan, L., Goodale, A. B., Alan, D., Sharpe, T., Shue, R. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45594-4 · Cited by 36
Enhanced antitumor activity of erlotinib in combination with the H sp90 inhibitor CH 5164840 against non‐small‐cell lung cancer
Ono, N., Yamazaki, T., Tsukaguchi, T., Fujii, T., Sakata, K., Suda, A., Tsukuda, T., Mio, T., Ishii, N., Kondoh, O., et al. (2013) · Cancer Science · doi:10.1111/cas.12237 · Cited by 34
Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations
Lv, N., Xie, X., Ge, Q., Lin, S., Wang, X., Kong, Y., Shi, H., Xie, X., & Wei, W. (2011) · Diagnostic Pathology · doi:10.1186/1746-1596-6-118 · Cited by 33
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
Cheng, H., An, S., Dong, S., Yi-fang, Z., Zhang, X., Chen, Z., Jian-Su, & Wu, Y.-L. L. C. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-5 · Cited by 32
Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival
Kim, G. W., Song, J. S., Choi, C., Rho, J. K., Kim, S. Y., Jang, S. J., Park, Y. S., Chun, S., Kim, W. S., Lee, J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.023 · Cited by 31
RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
Cho, J. H., You, Y.-M., Yeom, Y. I., Lee, D. C., Kim, B., Won, M., Cho, B. C., Kang, M., Park, S., Yang, S.-J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0651-5 · Cited by 31
Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss
Ding, H., Zhao, J., Zhang, Y. L., Yu, J., Liu, M., Li, X., Xu, L., Lin, M., Liu, C., He, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.043 · Cited by 28
MiR-1299 Impedes the Progression of Non-Small-Cell Lung Cancer Through EGFR/PI3K/AKT Signaling Pathway
Cao, S., Li, L., Li, J., & Zhao, H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s250396 · Cited by 31
Cheminformatics at the interface of medicinal chemistry and proteomics
Koch, U., Hamacher, M., & Nußbaumer, P. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.05.010 · Cited by 32
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Yamaoka, T., Ohmori, T., Ohba, M., Arata, S., Kishino, Y., Murata, Y., Kusumoto, S., Ishida, H., Shirai, T., Hirose, T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0313 · Cited by 32
AKT inactivation causes persistent drug tolerance to EGFR inhibitors
Tetsu, O., Phuchareon, J., Eisele, D. W., Hangauer, M. J., & McCormick, F. P. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.022 · Cited by 31
The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy
Ying, H.-Q., Chen, J., He, B.-S., Pan, Y.-Q., Wang, F., Deng, Q.-W., Sun, H.-L., Liu, X., & Wang, S.-K. (2015) · Scientific Reports · doi:10.1038/srep11348 · Cited by 29
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
Cardona, A. F., CLICaP, O. B. O. T., Rojas, L., Wills, B., Arrieta, O., Carranza, H., Vargas, C., Otero, J., Corrales-Rodriguez, L., Martín, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12112 · Cited by 29
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
Park, J., Cho, Y., Shin, W.-J., Lee, S. G., Lee, J.-H., Kim, T., Cha, P.-H., Yang, J. S., Cho, J., Min, D. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37059-8 · Cited by 30
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
Li, Y., Kong, S., Liu, Y., Yang, Y., & Zhang, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041438 · Cited by 29
The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors
Haines, E., Schlienger, S., & Claing, A. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1071737 · Cited by 28
Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer
Sirhan, Z., Alojair, R., Thyagarajan‐Sahu, A., & Sahu, R. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082090 · Cited by 28
Enhanced anti‐angiogenic effect of E 7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor‐resistant non‐small‐cell lung cancer xenograft models
Ito, K., Semba, T., Uenaka, T., Wakabayashi, T., Asada, M., & Funahashi, Y. (2014) · Cancer Science · doi:10.1111/cas.12450 · Cited by 29
Systems biology approaches to develop innovative strategies for lung cancer therapy
Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.28 · Cited by 27
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation
Zou, M., Xia, S., Zhuang, L., Han, N., Chu, Q., Chao, T., Peng, P., Chen, Y., Gui, Q., & Yu, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1895 · Cited by 28
AKT activation controls cell survival in response to HDAC6 inhibition
Kaliszczak, M. A., Trousil, S., Ali, T., & Aboagye, E. O. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.180 · Cited by 28
Membrane‐tethered Notch1 exhibits oncogenic property via activation of EGFR–PI3K–AKT pathway in oral squamous cell carcinoma
Zheng, Y., Wang, Z., Xiong, X., Zhong, Y., Zhang, W., Dong, Y., Li, J., Zhu, Z., Zhang, W., Wu, H., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27022 · Cited by 29
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
Creelan, B., Gray, J. E., Tanvetyanon, T., Chiappori, A., Yoshida, T., Schell, M. J., Antonia, S. J., & Haura, E. B. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0428-3 · Cited by 28
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
Grazini, U., Markovets, A. A., Ireland, L., O’Neill, D. J., Phillips, B., Xu, M., Pfeifer, M., Vaclová, T., Martin, M. J., Bigot, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2540 · Cited by 27
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers
Chatterjee, N., Pazarentzos, E., Mayekar, M. K., Gui, P., Allegakoen, D. V., Hrustanovic, G., Olivas, V. R., Lin, L., Verschueren, E., Johnson, J. R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.063 · Cited by 26
MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells
Maharati, A., Zangouei, A. S., Khalili‐Tanha, G., & Moghbeli, M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00840-4 · Cited by 28
PTEN-mediated resistance in cancer: From foundation to future therapies
Tufail, M. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101987 · Cited by 30
Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status
Pak, M. G., Lee, C. H., Lee, W.-J., Shin, D., & Roh, M.-S. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0339-4 · Cited by 26
Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection
Nishikawa, S., Menju, T., Takahashi, K., Miyata, R., Yoshikawa, T. F. C., Sonobe, M., Yoshizawa, A., Sabe, H., Sato, T. S., & Date, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200819 · Cited by 26
NETRIN-4 Protects Glioblastoma Cells FROM Temozolomide Induced Senescence
Li, L., Hu, Y., Ylivinkka, I., Li, H., Chen, P., Keski‐Oja, J., & Hyytiäinen, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080363 · Cited by 26
New apoptotic anti-triple-negative breast cancer theobromine derivative inhibiting EGFRWT and EGFRT790M: in silico and in vitro evaluation
Eissa, I. H., Yousef, R. G., Elkady, H., Alsfouk, A. A., Husein, D. Z., Ibrahim, I. M., El‐Deeb, N. M., Kenawy, A. M. A., Eldehna, W. M., Elkaeed, E. B., et al. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10644-4 · Cited by 25
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Xu, Z., Hang, J., Hu, J., & Gao, B. (2013) · Europe PMC (PubMed Central) · Cited by 25
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Presutti, D., Santini, S., Cardinali, B., Papoff, G., Lalli, C., Samperna, S., Fustaino, V., Giannini, G., & Ruberti, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143333 · Cited by 25
Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptor‐mutated non‐small‐cell lung cancer: A narrative review
Wang, X., Chen, B., Xu, D., Li, Z., Liu, H., Huang, Z., Huang, K., Lin, X., & Yao, H. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15360 · Cited by 25
Genetic alterations shaping tumor response to anti-EGFR therapies
Vaquero, J., Pavy, A., Gonzalez‐Sanchez, E., Meredith, M., Arbelaiz, A., & Fouassier, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100863 · Cited by 26
Progress in Glioma Stem Cell Research
Ramar, V., Guo, S., Hudson, B., & Liu, M. (2023) · Cancers · doi:10.3390/cancers16010102 · Cited by 27
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Delaney, C. D., Frank, S., & Huang, R. S. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0007-9 · Cited by 27
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency
Takeda, H., Takigawa, N., Ohashi, K., Minami, D., Kataoka, I., Ichihara, E., Ochi, N., Tanimoto, M., & Kiura, K. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.12.018 · Cited by 25
In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Anisuzzaman, A. S. M., Haque, A., Wang, D., Rahman, M. A., Zhang, C., Chen, Z., Chen, Z. G., Shin, D. M., & Amin, A. R. M. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0683 · Cited by 25
Clinicopathologic Features and Immune Microenvironment of Non–Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Takashima, Y., Sakakibara‐Konishi, J., Hatanaka, Y., Hatanaka, K. C., Ohhara, Y., Oizumi, S., Hida, Y., Kaga, K., Kinoshita, I., Dosaka‐Akita, H., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.02.004 · Cited by 25
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Ulivi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071186 · Cited by 24
Recent Advances in the Transition-Metal-Free Synthesis of Quinazolines
Tamatam, R., & Shin, D. (2023) · Molecules · doi:10.3390/molecules28073227 · Cited by 24
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Steen, N. V. D., Giovannetti, E., Carbone, D., Leonetti, A., Rolfo, C. D., & Peters, G. J. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.13 · Cited by 23
Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling
Peifer, M., Weiss, J. M., Sos, M. L., Koker, M., Heynck, S., Netzer, C., Fischer, S., Rode, H. B., Rauh, D., Rahnenführer, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008919 · Cited by 24
Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib
Banno, E., Togashi, Y., Velasco, M. A. D., Mizukami, T., Nakamura, Y., Terashima, M., Sakai, K., Fujita, Y., Kamata, K., Kitano, M., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3961 · Cited by 23
Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer
Zhang, Y., Qian, J., Fu, Y., Wang, Z., Hu, W., Zhang, J., Wang, Y., Guo, Y., Chen, W., Zhang, Y., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167447 · Cited by 23
Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer – Proof of concept towards a systems pharmacology approach
Saafan, H., Foerster, S., Parra-Guillen, Z. P., Hammer, E., Michaelis, M., Cinatl, J. J., Völker, U., Fröhlich, H., Kloft, C., & Ritter, C. A. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.025 · Cited by 23
Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis
Deng, Q., Fang, Q., Ji, X., & Zhou, S. (2020) · Journal of Cancer · doi:10.7150/jca.42850 · Cited by 23
M2 macrophages reduce the effect of gefitinib by activating AKT / mTOR in gefitinib‐resistant cell lines HCC827 / GR
Xiao, F., Liu, N., Ma, X., Qin, J., Liu, Y., & Wang, X. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13670 · Cited by 22
Antitumor Activity of Anti‐miR‐21 Delivered through Lipid Nanoparticles
Zhang, Z., Huang, Y., Li, J., Su, F., Kuo, J. C., Hu, Y., Zhao, X. B., & Lee, R. J. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202412 · Cited by 22
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
Stamatkin, C. W., Julian, K. L., Westendorf-Overley, C., & Black, E. P. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1070986 · Cited by 21
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
Schöttle, J., Chatterjee, S., Volz, C., Siobal, M., Florin, A., Rokitta, D., Hinze, Y., Dietlein, F., Plenker, D., König, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6276 · Cited by 22
Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer
Rose-James, A., & Sreelekha, T. T. (2012) · Lung Cancer International · doi:10.1155/2012/729532 · Cited by 23
Modular protein-DNA hybrid nanostructures as a drug delivery platform.
Ryu, Y., Hong, C. A., Song, Y., Beak, J., Seo, B. A., Lee, J.-J., & Kim, H.-S. (2020) · Nanoscale · doi:10.1039/c9nr08519j · Cited by 14
Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
Garay, T., Kenessey, I., Molnár, E., Juhász, É., Réti, A., László, V., Rózsás, A., Dobos, J., Döme, B., Berger, W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117021 · Cited by 22

Authors: Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., Michel, K., Peifer, M., Mermel, C., Girard, L., Peyton, M., Gazdar, A. F., Minna, J. D., Garraway, L. A., Kashkar, H., Pao, W., Meyerson, M., & Thomas, R. K.
Affiliations: Max Planck Society (DE)
Broad Institute (US)
Harvard University (US)
University of Cologne (DE)
The University of Texas Southwestern Medical Center (US)
Memorial Sloan Kettering Cancer Center (US)
ORCID: Sos, Martin L.
Rabinovsky, Rosalia
Zander, Thomas
Weiss, Jonathan
Frommolt, Peter
Michel, Kathrin
Peifer, Martin
Mermel, Craig
Girard, Luc
Peyton, Michael
Gazdar, Adi F.
Minna, John D.
Garraway, Levi A.
Kashkar, Hamid
Pao, William
Meyerson, Matthew
Thomas, Roman K.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2009-04-15
Volume: 69
Issue: 8
Pages: 3256-3261
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-08-4055
PMC: PMC2849653
OpenAlex: W2133488997
Cited by: 504
References: 21
Citations by year: 2026: 8 · 2025: 15 · 2024: 15 · 2023: 20 · 2022: 17 · 2021: 25 · 2020: 30 · 2019: 31 · 2018: 39 · 2017: 33 · 2016: 34 · 2015: 45 · 2014: 35 · 2013: 48 · 2012: 31
FWCI: 30.59
Type: journal article
Language: en
Update notices: correction (2025-03-03)
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Max Planck Institute for Plasma Physics (submittedVersion)
MPG.PuRe (Max Planck Society) (submittedVersion)
Funders: National Cancer Institute (R01CA116020, (P50-CA70907, P50CA070907)
National Institute of General Medical Sciences (T32GM007753)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: PTEN loss, erlotinib resistance, EGFR-mutant lung cancer, non-small cell lung cancer, Akt signaling, EGFR activation, EGFR inhibition, T790M mutation, MET amplification
MeSH terms: Erlotinib Hydrochloride, Carcinoma, Non-Small-Cell Lung, Chromosome Aberrations, Enzyme Activation, Humans, Lung Neoplasms, Quinazolines, Gene Expression, Cluster Analysis, Gene Deletion, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks